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Synopsis 
Background 
Carbapenem resistance in Gram-negative bacteria is increasing in many countries 
and use of carbapenems and antibiotics to which resistance is linked should be 
reduced to slow its emergence. There are no directly equivalent antibiotics and the 
alternatives are less well supported by clinical trials. The few new agents are 
expensive.  
Objective 
To provide guidance on strategies to reduce carbapenem usage. 
Methods 
Review of literature was performed as described in the Joint Working Party Report. 
Results 
Older agents remain active against some of the pathogens, although the 
expectations of broad spectrum cover for empirical treatment has risen. Education, 
expert advice on treatment and antimicrobial stewardship can produce significant 
reductions in use.   
Conclusions 
More agents may need to be introduced onto the antibiotic formulary of the hospital, 
despite the poor quality of scientific studies in some cases. 
Background 
The number of patients with infections caused by Gram-negative bacteria resistant to 
carbapenems is increasing.¹ However empirical use of these agents, especially 
meropenem, is rising because of anxiety to ensure empirical regimens for treating 
sepsis are active against a wide spectrum of pathogens, including those resistant to 
first line agents.2 National outbreaks of meropenem resistance have already been 
seen.1 Governments are now considering strategies to halt the rise in usage. A 
systematic literature review was conducted as part of a recent Working Party 
Report.¹ 
Using antimicrobials only when strictly indicated and preferably narrow spectrum (i.e 
antimicrobial stewardship) is the major defence against antimicrobial resistance other 
than infection control measures. Molecular tests for identification and resistance 
profile are becoming useful for targeting antimicrobial prescription. In England, the 
Chief Medical Officer has produced a strategy to limit the emergence of resistant 
organisms and is encouraging the pharmaceutical industry to invest in development 
of new agents.³  Unless alternative means of funding are devised, the need to restrict 
prescription of new agents to prevent emergence of resistance remains a 
disincentive to commercial investment.   
 
Multidrug resistant Gram-negative bacteria may be defined as having three or more 
antimicrobial resistance mechanisms affecting different antibiotic classes.² These 
include Enterobacteriaceae (Escherichia coli, Klebsiella spp., Enterobacter spp., 
Serratia spp., Citrobacter spp., Proteeae), and the non-fermenters: Pseudomonas 
aeruginosa, and Acinetobacter baumannii. The main concerns are those resistant to 
β-lactams, carbapenems, cephalosporins, β-lactamase inhibitor combinations and 
fluoroquinolones. Stenotrophomonas maltophilia is intrinsically resistant to 
carbapenem. Strains producing AmpC β-lactamases are resistant to penicillins 
(except temocillin), cephalosporins, aztreonam and penicillin-β-lactamase-inhibitor 
combinations. Extended spectrum β-lactamases (ESBL) confer resistance to 
cefotaxime, ceftriaxone and ceftazidime but are inhibited by clavulanic acid and 
tazobactam. Carbapenemases, for example KPC, VIM, IMP, NDM and OXA-48, 
confer resistance to meropenem and ertapenem. Carbapenem resistance due to 
ESBL or AmpC enzymes combined with porin loss may lead to treatment failure, for 
example with Pseudomonas aeruginosa.   
 
Evidence that carbapenem use and resistance are related depends mostly on 
observational and retrospective studies. Increased use of carbapenems, for example 
as the result of cephalosporin restriction, has been associated with increased 
carbapenem resistance in Acinetobacter sp and Pseudomonas aeruginosa 4-7. A 
matched case control study of multiply-resistant Acinetobacter in intensive care units 
reported similar findings.8 Conversely, decreased use of carbapenem following 
antibiotic restriction and education programs has been associated with reduced 
carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter sp.9-12  
 
A relationship between use of carbapenems and resistance in Enterobacteriaceae 
was not demonstrated in observational studies conducted in areas where prevalence 
of resistance was low.7,12-14 However, meropenem consumption was significantly 
correlated to resistance rates in E coli and Klebsiella pneumoniae where prevalence 
was high.15  Another study in UK evaluated the impact of antimicrobial stewardship 
using segmented regression analysis of interrupted time series and pharmacy 
consumption data.16 Reduced meropenem consumption was associated with 
reduction in the  incidence of OXA-48-producing K. pneumoniae .   
Although multidrug resistant organisms are often first recognised in hospitals, they 
are common in long-term care facilities.17 Resistance to several types of antibiotic 
can be carried on a single transferable genetic element. Treatment with 
carbapenems, aminoglycosides or cephalosporins can be associated with acquisition 
of resistance to ciprofloxacin as much as following treatment with ciprofloxacin 
itself.18 These organisms can remain in the gut for a up to a year. 
Enterobacteriaceae, P. aeruginosa and Acinetobacter, whether resistant or not, can 
be transferred between patients by staff or environment. Although outbreaks of a 
single species of resistant organism can be recognised and controlled, some 
outbreaks involve plasmids passed between species.19 P. aeruginosa may be 
resistant through many mechanisms including reduced permeability. The organism is 
associated with water sources in the environment and can be transmitted following 
hand hygiene.² 
 
To prevent these organisms spreading requires a high level of compliance to 
standard infection control precautions (SICP) including hand hygiene, use of 
personal protective equipment and a clean environment.² A national intervention in 
Israel with mandatory patient screening, cohorting of staff and source isolation was 
effective in controlling an outbreak of carbapenemase-producing K. pneumoniae.20 
Rectal swabs for screening at admission identify and allow isolation of carriers but 
the cost and need for an invasive investigation has limited adoption of routine 
screening. Control of carbapenemase–producing K. pneumoniae has failed in 
Greece and Italy.21  
 In patients with haematological malignancies, colonization with ESBL-producing 
Enterobacteriaceae has been reported in 5.3- 21.8% of patients, encouraging 
empirical carbapenem usage.22 Carriage continues in at least 45% of patients for 
over 6 months.23 Selective decontamination with non-absorbable as well as 
intravenous antibiotic only suppresses carriage transiently24 and can be associated 
with emergence of resistance to the antibiotics used but may prevent some 
subsequent infections.25 
 
Evidence for specific antimicrobials (Table 1) 
Carbapenems 
Meropenem and imipenem-cilastatin are very broad spectrum agents used in 
hospital-acquired infections when the primary antibiotic regimen has failed or 
resistance is suspected, for example, infections due to extended spectrum β-
lactamase producers.26 Ertapenem is not active against Pseudomonas or 
Acinetobacter and may be more likely than meropenem to select mutational 
resistance via porin loss in ESBL-producing Klebsiella sp and Enterobacter sp.27  
 
The common indications for treatment with a carbapenem are urinary infections 
resistant to other antibiotics, intra-abdominal infection, acute pancreatitis and 
prevention of necrotizing pancreatitis, nosocomial pneumonia, bacterial meningitis, 
cystic fibrosis and febrile neutropenia.26 In some countries, such as UK, the majority 
of prescriptions follow discussion with a microbiologist, providing the opportunity for 
an effective intervention. However elsewhere influencing choice may be much more 
difficult. Although not a major cause of quinolone resistance, the widespread use of 
ciprofloxacin for prophylaxis in neutropenic patients may be a driver for linked 
resistances and increased use of carbapenems.28 The use of meropenem to treat 
infections due to carbapenem-resistant Enterobacteriaceae is another potential risk 
and arises from some retrospective evidence that combinations including 
meropenem may reduce mortality.29  
 
Alternative antimicrobial drugs  
With very few new agents in prospect, older antibiotics effective against Gram- 
negative bacteria have been re-examined. Rather than choosing meropenem by 
default, piptazobactam can be used to treat susceptible ESBL-producing 
Enterobacteriaceae. In the UK, Working Party guidelines on treatment are soon to be 
published and provide detailed guidance (P Hawkey, personal communication).  
  
The first group of alternatives are widely available in hospitals already: 
 
Co-trimoxazole (trimethoprim/sulfamethoxazole) is the primary treatment for 
infections with Stenotrophomonas maltophilia .30  It has a broad spectrum of inherent 
antibacterial activity, including Enterobacteriaceae, and Haemophilus sp although not 
P. aeruginosa. Severe though rare side effects, such as Stevens-Johnson syndrome, 
and frequent resistance to trimethoprim have limited its use. 
 
Colistin (Polymyxin E) is a current rescue choice for treating infection with 
carbapenem-resistant Gram-negative organisms. It should not be used as a 
substitute for carbapenem. It is not active against Proteus spp. or Serratia spp. 
Studies of treatment of multidrug resistant bacterial infections have been uncontrolled 
and of small size31 and there are fears of under-dosing at current licensed doses.32 
Higher doses and use in combination may be needed for severe infections or where 
resistance is endemic. The main adverse effects are nephrotoxicity and neurotoxicity. 
The UK is one of the largest users of the antibiotic, mostly inhaled for management of 
cystic fibrosis. 
 
Rifampicin has a broad spectrum of activity but resistance develops readily and use 
is not recommended. There are no in vitro breakpoint recommendations and its 
activity is probably a synergistic effect.33 
 
Aminoglycosides remain active in vitro against more than 90% of E. coli, Klebsiella 
spp. and Enterobacter spp bloodstream and urine isolates reported in UK and can be 
useful in combination regimens.34,35  However, over half of Enterobacteriaceae 
producing CTX-M extended spectrum -lactamases can be resistant to gentamicin.36 
Although persistent asymptomatic bacteriuria may occur, aminoglycosides can be 
safely used in the treatment of urinary infection.37 
 
The second group of agents are available on the formulary of some hospitals but if 
an application to the hospital Drug and Therapeutics Committee has to be made, it 
may be challenging in view of the additional cost and limited supporting controlled 
clinical trials. 
 
Temocillin is a derivative of ticarcillin, which is stable to some β-lactamases. It is 
effective against ESBL and AmpC-producing Enterobacteriaceae but not 
Pseudomonas or Acinetobacter. Clinical studies are retrospective but suggest it can 
be used to treat multi-resistant urinary infection, although relatively expensive.38   
 
Aztreonam has activity only against aerobic Gram-negative bacteria (although P. 
aeruginosa is only moderately susceptible). It has been used to treat serious Gram-
negative infections and it is safe in penicillin allergy. It may be hydrolysed by 
extended spectrum β-lactamases but is stable to some metallo- β-lactamases. A 
Japanese study suggested similar efficacy sulbactam/ampicillin plus aztreonam 
versus piperacillin/tazobactam plus ceftazidime in febrile episodes paediatric 
haematology or oncology but carbapenems were not included.39   
 
Fosfomycin has been used as an oral agent (single dose) for treating multiresistant 
lower urinary infections. It is primarily active against E. coli (including ESBL), 
Citrobacter and Proteus mirabilis. Intravenous fosfomycin is now more widely 
available but is significantly more expensive than other antibiotics.  In combination 
with colistin or tigecycline, clinical success was reported in 54% of 48 critically ill 
patients as salvage therapy and a carbapenem-sparing regimen.40   
 
Tigecycline is active against Gram-negative bacteria, including Acinetobacter but not 
P. aeruginosa and Proteeae. In a double blind randomised comparison of treatment 
of soft tissue infection, clinical response was similar to vancomycin/aztreonam (86% 
versus 88%).41 A double blind randomised comparison with imipenem for 
complicated intra-abdominal infection (5-14 days) showed similar rate of clinical cure 
at 14-35 days (81% and 82% n=825).42 However it was inferior to imipenem in the 
treatment of ventilator-associated pneumonia.43 Tigecycline should only be used 
when other antibiotics are not suitable because meta-analyses have shown lower 
cure rates and higher mortality than comparators.44 Recent research has explored 
higher doses.45  
 
Mecillinam, although a β-lactam antibiotic, resists hydrolysis by common β-
lactamases. The oral prodrug, pivmecillinam, is used to treat lower urinary tract 
infection but usually is not active against carbapenemase-producing organisms. Only 
case series are published covering treatment of ESBL-producing 
Enterobacteriaceae.46  
 
Chloramphenicol has a broad spectrum of activity. Overall resistance in E. coli in UK 
fell from 20.2% in 1991 to 7.9% in 2004 with a decrease in use but there is more 
resistance in strains causing bacteremia.47 Clinical trials are mostly restricted to 
enteric, ophthalmic and central nervous system infections. However it can cause 
dose-related or idiosyncratic haemopoietic toxicity and rarely aplastic anaemia.  
 
Ceftolozane/tazobactam is active against Gram-negative bacteria including 
Pseudomonas against which its activity is comparable to colistin.48 Although ESBL-
producing organisms are often susceptible, the antibiotic is not effective against 
producers of metallo-β-lactamases, or KPC or OXA-48 strains. It has limited Gram-
positive activity and is not active against anaerobes. In a randomised controlled trial 
in abdominal sepsis, the cure rate in combination with metronidazole was not inferior 
to meropenem (83% versus 87% n=993)48,49 Against levofloxacin in 1083 patients 
with urinary infection, it was not inferior. Adverse effects were not found to be 
significantly different from comparator agents.50  
 Sulbactam is β-lactamase inhibitor often used in combination with ampicillin and is 
available in many countries (but not UK). It can be used to treat Acinetobacter 
infection, although activity is limited .51 In complicated soft tissue infections efficacy is 
similar to tigecycline (77.6% versus 77.5%).52 
 
Ceftazidime/avibactam has recently been licensed in Europe. It is active against most 
Gram negative bacteria except Acinetobacter. Producers of ESBL, OXA-48 and KPC 
(but not metallo β-lactamase) are susceptible.48 Efficacy (combined with 
metronidazole) was similar to meropenem in treatment of intra-abdominal infection 
and as monotherapy to imipenem in treating complicated urinary infection.48 However 
the development of resistance during treatment of infection due to Klebsiella 
pneumoniae has resulted in failures, although mutation may restore carbapenem 
susceptibility.53 Combination with aminoglycoside may be needed. 
 
None of the alternatives to carbapenems can match their spectrum of activity if used 
as monotherapy. Therefore to reduce carbapenem usage, prescribers need to 
identify patients in whom the extent of antimicrobial coverage is not required or can 
be rapidly de-escalated or where a combination of other agents could be used 
instead. 
 
Current antimicrobial usage 
The use of carbapenems is increasing, partly as the result of suspected rising 
prevalence of multi-resistant Gram-negative pathogens and partly decreased use of 
cephalosporins and quinolones intended to limit Clostridium difficile. There has been 
a concurrent rise in the use of piptazobactam. The English Surveillance Programme  
for Antimicrobial Utilization and Resistance (ESPAUR) report¹ found that although 
carbapenems formed only 0.3% of overall antibiotic consumption in 2013, use 
increased by 31.3% in England between 2010 and 2013. Meropenem accounted for 
89% of total carbapenem consumption.  
 
The speed of treatment of septic patients with a broad spectrum antibiotic is 
increasingly used as a performance indicator and may counteract the stewardship 
principle of using narrower spectrum empiric agents. Quality improvement 
programmes such as the Sepsis Six Pathway, encompass a bundle of measures 
developed to reduce mortality of patients with sepsis. Empirical broad spectrum 
intravenous antibiotic has to be delivered within 1 hour of diagnosis. Starting 
antibiotic treatment within 3 and 6 hours is associated with lower mortality and the 1 
hour threshold has been inferred.54 This may promote carbapenem use at first 
presentation with or without subsequent de-escalation.  
 
Current Stewardship Initiatives 
A recent Cochrane review has shown interventions to reduce excessive antibiotic 
prescribing in hospitals reduce antimicrobial resistance without detriment to clinical 
outcome.55 On the other hand, interventions that increase effective prescribing can 
improve clinical outcome, assuming the pathogen is susceptible to the empirical 
treatment. Restrictive interventions have a greater impact on short term prescribing 
outcome than persuasive ones. Surveillance and active feedback to prescribers 
should include the clinical outcome of bacteremia and the antibiotic used.  
 
In UK, NICE56 recommends antimicrobial stewardship in all settings with regular 
monitoring and feedback of usage. Repeated review is recommended to ensure 
antibiotics are given only when necessary and stopped as soon possible. It 
advocates decision support software which may be useful in implementing 
carbapenem-sparing regimens. Lew et al 57 found de-escalation of carbapenem 
treatment in an acute care setting encountering multiresistant Gram-negative 
infections had no effect on survival and there were fewer acquisitions of 
carbapenem-resistant Acinetobacter. In a carbapenem-sparing programme, 
temocillin was used for treating urinary tract infections and hospital-acquired 
pneumonia involving ESBL organisms.58 Aztreonam and ciprofloxacin were used as 
alternatives to gentamicin in combination for treatment in febrile neutropenia.59 
 
Studies of combination regimens for treatment of carbapenem-resistant infections are 
poor quality and heterogeneous.59 Patients treated with a combination regimen 
including polymyxin have a lower mortality at 30 days than patients treated with 
polymyxins alone.60 Similarly, for infections caused by carbapenemase-producing K. 
pneumoniae, mortality was lower when two or more active antimicrobials were used 
compared with monotherapy.61 Survival was improved with combinations including 
tigecycline, colistin and high-dose meropenem. Combinations including gentamicin 
resulted in reduced mortality when colisitin resistance was present.62 Tigecycline in 
combination regimens was only assessed in observational studies.63  
 
In clinical practice, the choice of alternative agents needs to be adjusted according to 
local existing susceptibility patterns. If a hospital is overwhelmingly reliant on one or 
two antibiotics proliferation of resistant organisms can be rapid. A diversity of 
antibiotic use as well as synergistic combination regimens is advisable but requires 
resource to allow monitoring.64 The infection specialist has an important role in this 
respect for individual patient management. 
 
Strategies for reducing carbapenem use 
A package of measures for reduction of carbapenem will usually be needed, the 
components of which depend on local circumstances and prevalence of resistance. A 
multidisciplinary team approach involving microbiologists, infectious diseases 
physicians and antimicrobial pharmacists is required. Advice should aim to ensure 
prescriptions are appropriate and stopped when signs of infection have resolved. 
Dose reduction carries a risk of under-treatment and is not effective in overcoming 
resistance where MIC>128 mg/L, although longer infusion may be beneficial for 
meropenem.65,66   
 
Local measures 
A number of strategies are being used to reduce carbapenem usage: 
Education 
Education of all grades of doctors is important in addressing the indications for using 
carbapenems and when and how treatment can be de-escalated. Mandatory e-
learning programs are used widely but behavioural change is difficult to achieve 
particularly in the more senior staff.  Unfortunately education programmes are usually 
reported only as a component of an intervention package including screening, 
cleaning, antimicrobial stewardship and source isolation.67,68 Trainee-led 
computerised ‘time-out’ audits conducted twice a week resulted in adjustment of 
antibiotic prescriptions in 15% of patients treated for infection. Although changes in 
carbapenem comprised only 6% of changes made during audit, the majority of cost 
savings ($54000 in 2 years) was due to reduction in meropenem use.69 If prescribers 
take responsibility for education programmes and audit themselves, these can be 
inexpensive and effective measures.  
Changing the Formulary 
Adjusting the hospital formulary to encourage the use of alternatives to carbapenem 
is effective. However simply switching to other agents is expensive. Instead  
heterogenous use of antibiotics can reduce emergence of multiresistant Gram 
negative infections.  In one study 70 when antibiotic choice was changed every three 
months according to resistance and usage density, carbapenem usage fell from 58% 
to 31% and isolation of multiresistant Gram negative bacteria fell from 1.7% to 0.5% 
over 18 months.  The number of patients from whom metallo-β-lactamase-producing 
organisms were isolated out of those from whom Gram negative pathogens were 
isolated fell significantly from 1.2% to 0.3%.   
Smartphone applications are an easily accessed and updated format for antimicrobial 
formularies. In one study, an antimicrobial application encouraged challenging of 
inappropriate prescriptions and knowledge of stewardship, but it was overruled by 
some senior physicians.71  Compliance with formulary is nevertheless promoted.  
Susceptibility Reporting 
Meropenem susceptibility may not be routinely released in pathology reports. 
Changing the order of presentation of susceptibilities can be effective, if the software 
allows, or encourage discussion with the microbiologist or infectious diseases 
physician. An antibiotic is more likely to be prescribed if the susceptibility has been 
released in the microbiology report.72 However, susceptibility release did not 
influence the appropriateness of antibiotic therapy. The microbiologist was contacted 
in response to 19% of 169 reports but in the 22% of remaining reports where 
antibiotic treatment was changed only one fifth were appropriate.  
Stewardship rounds 
Although both microbiologists/infectious disease physicians and pharmacists advise 
on treatment of individual patients, joint antimicrobial stewardship reviews of ward 
patients are becoming common. In both cases, advice on alternatives to 
carbapenems can usually be given. De-escalation and stopping of antibiotics are 
effective stewardship measures. The main limitation is the low number of patients 
that can be covered in the time available. The treating team may not be contactable 
at the time and the reason for antibiotic prescription may not be well documented or 
clinical notes available. In one study sufficient resources were made available for 
infection control team visits to all patients on intravenous antibiotics, with twice 
weekly review of carbapenem prescriptions, followed by telephone contact with the 
clinician.68 Coupled with an education programme, these measures were effective in 
reducing carbapenem usage significantly. In particular inappropriate course length 
was reduced. A full time pharmacist was required for the work. However, the rate of 
carbapenem-resistant infections was unchanged. Restriction of antibiotic 
prescription, for example by an authorisation code from microbiology, is effective in 
the short term but time consuming. In a cross-over study comparing pre-prescription 
authorization versus post-prescription review and feedback (n=2686, 2693, 29% 
versus 27% given antibiotic), the latter had a greater impact in reducing days of 
antibiotic treatment and should be given priority.73  
Electronic Prescribing 
Electronic prescribing can be helpful in providing continuous audit and feedback of 
prescription levels to clinical teams. However a survey of 13 UK hospitals found no 
relationship between use of such a system and compliance with antimicrobial 
stewardship guidelines.74 Computer decision support systems can be standalone, 
incorporated in electronic record, based on surveillance or used for antibiotic pre-
prescription authorisation.75 System interventions increased appropriate use of 
antimicrobials in a meta-analysis (pooled RR: 1.49, 95%CI: 1.07-2.08). However 
when only high quality studies were included the benefit was not apparent.  
 
Whichever measures are adopted based on local availability of resources, a 
carbapenem-sparing strategy should be agreed between the stakeholders and the 
local Drug & Therapeutics Committee.  
 
National measures 
Governments can apply incentives for hospitals to formulate a strategy. Routine 
collection of carbapenem prescription data and feedback reveals the outliers in 
numbers of prescriptions.  Measures to slow the rise in carbapenem prescriptions are 
already being used in some countries and in UK antibiotic prescription rates are now 
available for public scutiny.76  
 
Putting plans into action 
New prescriptions using carbapenem-sparing regimens can be advised whenever 
microbiologists or infectious diseases physicians are consulted. Diversity of 
prescribing can be promoted by advice to use cephalosporins and quinolones, 
although these agents are discouraged when rates of MRSA and C difficile are high. 
A decision support system linked to an antimicrobial App is a potential aid. 
Documented antimicrobial advice should be supported by regular antimicrobial audit 
to assess compliance. Introduction of a greater diversity onto the hospital formulary 
should be considered but stakeholders should be consulted. When considering 
additions to the formulary, the paucity of clinical trial evidence has to be balanced 
against the impending problem of multiresistance.56  
 
For severe infections known or suspected to be resistant to first line agents, 
temocillin, colistin or ceftazolone/tazobactam can be used instead of a carbapenem. 
For uncomplicated lower urinary infections, fosfomycin, pivmecillinam or 
nitrofurantoin is appropriate if the pathogen is susceptible. If resistance to 
meropenem and the above agents is known or suspected, tigecycline, intravenous 
fosfomycin, ceftazidime/avibactam (not for metallo-β-lactamase producers) or 
combinations including colistin or high dose meropenem can be considered. The 
genetic basis of carbapenem resistance is important in predicting the likely efficacy of 
a treatment choice and needs to be based in hospital laboratory rather than the 
reference laboratory.¹  
 
Conclusions 
Carbapenem reduction can be achieved by education, local stewardship rounds and 
national prescription data collection and feedback. The microbiologists themselves 
can have a major effect through restrictive advice if the hospital practice is to seek 
their advice. Alternative antimicrobial strategies may involve combinations of 
antibiotics but evidence base of clinical trials is poor for some older agents and 
needs to be improved urgently.  
 
Recommendations 
High efficacy, low cost 
1. Clinician-led education and audit 
2. Formulary presenting a diversity of antibiotic choices with support of a 
Smartphone application and liaison advice from microbiology and infectious 
disease physicians 
 
Low Efficacy, low cost  
1. Antimicrobial susceptibility release in microbiology reports to influence 
prescribing 
 
Moderate efficacy, high cost  
1. Post prescription review and feedback as part of antimicrobial stewardship 
round with aim of de-escalation, appropriate course length and reduced 
unnecessary use of carbapenem. 
 
Low efficacy, high cost  
1. Microbiology authorisation code pre-prescription to restrict antibiotic use 
2. Electronic prescribing systems for decision support 
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Table 1. Meropenem and alternative antimicrobials 
 
Animicrobial Indication Gram-negative 
Activity 
Adverse effect 
    
Aztreonam Gram-negative 
bacteremia, 
osteomyelitis, 
respiratory, febrile 
neutropenia 
Gram negative 
aerobic bacilli except 
ESBL or AmpC 
producers 
Bronchospasm, 
rash 
Ceftazidime - 
avibactam 
ESBL, OXA-48 & 
KPC, abdominal, 
urinary. 
Combination with 
aminoglycoside. 
Broad except 
Acinetobacter, 
metallo- β-
lactamase.  
Nausea, 
diarrhoea, 
Coombs positive, 
rash 
Ceftolozane-
tazobactam 
ESBL producers, 
abdominal, urinary  
Broad except 
metallo- β-
lactamase, KPC and 
OXA-48.  
Headache, 
nausea, diarrhoea 
Chloramphenicol Abdominal, 
meningitis, 
respiratory 
Broad except 
Pseudomonas sp 
Idiosyncratic and 
dose related 
haemopoietic 
toxicity  
Colistin Carbapenem 
resistance Gram 
negatives in 
combination 
Broad except 
Proteus sp, Serratia 
sp 
Nephrotoxicity, 
neurotoxicity 
Co-trimoxazole  Stenotrophomonas 
maltophilia  
Enterobacteriaceae, 
Haemophilus 
influenzae not P 
aeruginosa 
Headache, 
diarrhoea, 
hyperkalemia, 
rash; rarely 
Stevens-Johnson 
Ertapenem Urinary, abdominal, 
respiratory, 
outpatient ESBL- 
producers 
Broad except P 
aeruginosa, 
Acinetobacter 
Diarrhoea, 
headache, 
pruritus, rash, 
vomiting 
Fosfomycin IV Combination 
regimen in ICU 
Escherichia coli, 
Citrobacter, Proteus 
mirabilis 
Dyspnoea, 
fatigue, heaache 
Fosfomycin oral Urinary ESBL 
producers 
Escherichia coli, 
Citrobacter, Proteus 
mirabilis 
Diarrhoea, 
dizziness, 
headache 
Gentamicin Combination 
regimens only 
E coli, Klebsiella sp, 
Enterobacter sp (not 
CTX-M) 
Nephrotoxicity, 
ototoxicity 
Imipenem Urinary, abdominal, 
respiratory, ESBL- 
producers 
Very broad Diarrhoea, 
vomiting, rash 
Pivmecillinam Urinary,  ESBL Broad Abdominal pain, 
producers dizziness, 
headache, 
vomiting 
Meropenem Urinary, abdominal, 
respiratory, 
meningitis, febrile 
neutropenia, ESBL- 
producers 
Very broad Abdominal pain, 
diarrhoea, 
headache, rash, 
vomiting 
Piptazobactam Urinary, abdominal, 
respiratory, febrile 
neutropenia, 
Susceptible ESBL-
producers 
Broad Rash, 
hypersensitivity, 
nausea, vomiting 
Rifampicin Synergistic in 
combination 
regimens 
Broad Liver function 
abnormality, renal 
failure, headache, 
Sulbactam Combination with 
ampicillin, soft 
tissue 
Acinetobacter Diarrhoea, 
vomiting, 
hypersensitivity 
Temocillin Urinary, ESBL-
producers 
Broad except 
Pseudomonas or 
Acinetobacter 
Diarrhoea, 
hypersensitivity 
rash 
Tigecycline Soft tissue, 
abdominal 
Broad except 
Pseudomonas 
Proteeae 
Higher mortality, 
abdominal pain, 
dizziness, 
headache 
    
  
References 
1. Wilson APR, Livermore DM, Otter JA, et al. Prevention and control of multi-
drug-resistant Gram-negative bacteria: recommendations from a Joint 
Working Party. J Hosp Infect 2016; 92: Suppl 1: S1-S44 
2. Ashiru-Oredope D, Hopkins S. English Surveillance Programme for 
Antimicrobial Utilization and Resistance Oversight Group. Antimicrobial 
stewardship: English Surveillance Programme for Antimicrobial Utilization and 
Resistance (ESPAUR).J Antimicrob Chemother. 2013;68:2421-3.  
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/
477962/ESPAUR_Report_2015.pdf 
3. Department of Health 2013. UK 5 Year Antimicrobial Resistance Strategy 
2013 to 2018.  
https://www.gov.uk/government/publications/uk-5-year-antimicrobial-
resistance-strategy-2013-to-2018 
4. Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of 
acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet. 
1994;344:1329–1332. 
5. Rahal JJ, Urban C, Segal-Maurer S. Nosocomial antibiotic resistance in 
multiple gram-negative species: Experience at one hospital with squeezing the 
resistance balloon at multiple sites. Clin Infect Dis 2002;34:499–503.  
6. Mladenovic-Antic S, Kocic B, Velickovic-Radovanovic R, et al. Correlation 
between antimicrobial consumption and antimicrobial resistance of 
Pseudomonas aeruginosa in a hospital setting: a 10-year study. J Clin Pharm 
Ther. 2016;41:532-7.  
7. Zou YM, Ma Y, Liu JH, et al. Trends and correlation of antibacterial usage and 
bacterial resistance: time series analysis for antibacterial stewardship in a 
Chinese teaching hospital (2009-2013). Eur J Clin Microbiol Infect Dis. 2015; 
34:795-803.  
8. Tsai HT, Wang JT, Chen CJ, et al.  Association between antibiotic usage and 
subsequent colonization or infection of extensive drug-resistant Acinetobacter 
baumannii: a matched case-control study in intensive care units. Diagn 
Microbiol Infect Dis. 2008; 62:298-305.  
9. Altunsoy A, Aypak C, Azap A, et al. The impact of a nationwide antibiotic 
restriction program on antibiotic usage and resistance against nosocomial 
pathogens in Turkey. Int J Med Sci. 2011;8:339-44. 
10. Fukushima Y, Fukushima F, Kamiya K, et al. Relation between the 
antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa 
from respiratory specimens and antimicrobial use density (AUD) from 2005 
through 2008. Intern Med. 2010;49:1333-40.  
11. Hsu LY, Tan TY, Tam VH, et al. Surveillance and correlation of antibiotic 
prescription and resistance of Gram-negative bacteria in Singaporean 
hospitals.  Antimicrob Agents Chemother. 2010;54:1173-8. 
12. Mutnick AH, Rhomberg PR, Sader HS, et al. Antimicrobial usage and 
resistance trend relationships from the MYSTIC Programme in North America 
(1999-2001). J Antimicrob Chemother. 2004;53:290-6.  
13. Ho CM, Ho MW, Liu YC, et al. Correlation between carbapenem consumption 
and resistance to carbapenems among Enterobacteriaceae isolates collected 
from patients with intra-abdominal infections at five medical centers in Taiwan, 
2006-2010. Int J Antimicrob Agents. 2012; 40 Suppl: S24-8.  
14. Jacoby TS, Kuchenbecker RS, Dos Santos RP, et al. Impact of hospital-wide 
infection rate, invasive procedures use and antimicrobial consumption on 
bacterial resistance inside an intensive care unit. J Hosp Infect. 2010;75:23-7.  
15. Joseph NM, Bhanupriya B, Shewade DG, et al. Relationship between 
Antimicrobial Consumption and the Incidence of Antimicrobial Resistance in 
Escherichia coli and Klebsiella pneumoniae Isolates. J Clin Diagn Res. 
2015;9:DC08-12. 
16. Gharbi M, Moore LS, Gilchrist M, et al. Forecasting carbapenem resistance 
from antimicrobial consumption surveillance: Lessons learnt from an OXA-48-
producing Klebsiella pneumoniae outbreak in a West London renal unit. Int J 
Antimicrob Agents. 2015;46:150-6.  
17. Rooney PJ, O'Leary MC, Loughrey AC, et al. Nursing homes as a reservoir of 
extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant 
Escherichia coli. J Antimicrob Chemother 2009; 64:635–641.  
18. Schechner V, Temkin E, Harbarth S, et al. Epidemiological Interpretation of 
Studies Examining the Effect of Antibiotic Usage on Resistance. Clin Microbiol 
Rev 2013; 26:289-307. 
19. Munoz-Price LS, Poirel L, Bonomo RA et al. Clinical epidemiology of the 
global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect 
Dis  2013; 13: 785-796.  
20. Schwaber MJ, Carmeli Y. An ongoing national intervention to contain the 
spread of carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 2014; 
58:697–703.  
21. Magiorakos A, Suetens C, Monnet DL, et al. The rise of carbapenem 
resistance in Europe: just the tip of the iceberg? Antimicrob Resis Infect 
Control 2013; 2:6.  
22. Vehreschild MJ, Hamprecht A, Peterson L, et al. A multicentre cohort study on 
colonization and infection with ESBL-producing Enterobacteriaceae in high-
risk patients with haematological malignancies. J Antimicrob Chemother 2014; 
69:3387-92.  
23. Zimmerman FS, Assous MV, Bdolah-Abram T, et al. Duration of carriage of 
carbapenem-resistant Enterobacteriaceae following hospital discharge. Am J 
Infect Control 2013; 41:190–194.  
24. Daneman N, Sarwar S, Fowler RA, et al. Effect of selective decontamination 
on antimicrobial resistance in intensive care units: a systematic review and 
meta-analysis. Lancet Infect Dis 2013;13:328–341.   
25. Halaby T, Al Naiemi N, Kluytmans J, et al.  Emergence of colistin resistance in 
Enterobacteriaceae after the introduction of selective digestive tract 
decontamination in an intensive care unit. Antimicrob Agents Chemother. 
2013; 57:3224-9.  
26. Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its 
use in the treatment of serious bacterial infections. Drugs. 2008;68:803-38. 
27. Garcıa-Fernandez A, Miriagou V, Papagiannitsis CC, et al. An ertapenem-
resistant extended-spectrum-beta-lactamase producing Klebsiella 
pneumoniae clone carries a novel OmpK36 porin variant. Antimicrob Agents 
Chemother 2010; 54:4178-4184. 
28. Garnica M, Nouer SA, Pellegrino FLPC et al. Ciprofloxacin prophylaxis in high 
risk neutropenic patients: effects on outcomes, antimicrobial therapy and 
resistance. BMC Infect Dis 2013; 13:356 
29. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing 
Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic 
combination schemes and the role of carbapenems. Antimicrob Agents 
Chemother 2014; 58, 2322-2328 
30. Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a 
serious bacterial pathogen in patients with cancer. Clin Infect Dis. 2007; 
45:1602-9. 
31. Koomanachai P, Tiengrim S, Kiratisin P, et al. Efficacy and safety of colistin 
(colistimethate sodium) for therapy of infections caused by multidrug resistant 
Pseudomonas aeruginosa and Acinetobacter baumanni in Siriraj Hospital, 
Bangkok, Thailand. Int J Infect Dis 2007; 11: 402-6. 
32. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of 
colistin methanesulfonate and formed colistin in critically ill patients from a 
multicenter study provide dosing suggestions for various categories of 
patients. Antimicrob Agents Chemother. 2011; 55:3284-94. 
33. Zavascki AP, Bulitta JB, Landersdorfer CB. Combination therapy for 
carbapenem-resistant Gram-negative bacteria. Exp Rev Anti Infect Ther 2015; 
11: 1333-53. 
34. Livermore DM, Hope R, Reynolds R, et al. Declining cephalosporin and 
fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae 
from the UK: links to prescribing change? J Antimicrob Chemother. 2013;68: 
2667-74. 
35. Ironmonger D, Edeghere O, Bains A, et al. Surveillance of antibiotic 
susceptibility of urinary tract pathogens for a population of 5.6 million over 4 
years. J Antimicrob Chemother. 2015; 70:1744-50. 
36. Xu L, Shabir S, Bodah T, et al. Regional survey of CTX-M-type extended-
spectrum β-lactamases among Enterobacteriaceae reveals marked 
heterogeneity in the distribution of the ST131 clone. J Antimicrob Chemother 
2011; 66: 505-511 
37. Vidal L, Gafter-Gvili A, Borok S, et al. Efficacy and safety of aminoglycoside 
monotherapy: systematic review and meta-analysis of randomized controlled 
trials. J Antimicrob Chemother. 2007; 60:247-57. 
38. Balakrishnan I, Awad-El-Kariem FM, Aali A, et al. Temocillin use in England: 
clinical and microbiological efficacies in infections caused by extended-
spectrum and/or derepressed AmpC β-lactamase-producing 
Enterobacteriaceae. J Antimicrob Chemother. 2011; 66:2628-31.  
39. Kobayashi R, Sato T, Nakajima M, et al. Piperacillin/tazobactam plus 
ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy 
for fever in severely neutropenic pediatric patients.J Pediatr Hematol 
Oncol.2009; 31:270-3.  
40. Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care 
unit patients treated with fosfomycin for infections due to pandrug-resistant 
and extensively drug-resistant carbapenemase-producing Gram-negative 
bacteria. Int J Antimicrob Agents.2014; 43:52-9.  
41. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in 
treatment of skin and skin structure infections: results of a double-blind phase 
3 comparison study with vancomycin-aztreonam. Antimicrob Agents 
Chemother. 2005; 49:4658-66. 
42. Oliva ME, Rekha A, Yellin A, et al.  A multicenter trial of the efficacy and safety 
of tigecycline versus imipenem/cilastatin in patients with complicated intra-
abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov 
Identifier: NCT00081744]. BMC Infect Dis. 2005; 5:88 
43. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with 
imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn 
Microbiol Infect Dis. 2010 ;68:140-51 
44. Yahav D, Lador A, Paul M, et al. Efficacy and safety of tigecycline: a 
systematic review and meta-analysis. J Antimicrob Chemother. 2011; 
66:1963-71 
45. Ramirez J, Dartois N, Gandjini H, et al. Randomized phase 2 trial to evaluate 
the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-
cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents 
Chemother. 2013 ;57:1756-62. 
46. Jansåker F, Frimodt-Møller N, Sjögren I, et al. Clinical and bacteriological 
effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella 
pneumoniae in urinary tract infections. J Antimicrob Chemother. 2014; 69:769-
72. 
47. Bean DC, Livermore DM, Papa I, et al. Resistance among Escherichia coli to 
sulphonamides and other antimicrobials now little used in man. J Antimicrob 
Chemother. 2005; 56:962-4.  
48. Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and 
ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination 
agents for the treatment of resistant Gram-negative bacterial infections. 
Internat J Antimicrob Ag 2015; 46: 266-271.  
49. Solomkin J, Hershbeger E, Miller B, et al. Complicated Intra-abdominal 
infections in an era of multidrug resistance: results from a randomized, double-
blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis 2015; 60: 1462-71. 
50. Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam 
compared with levofloxacin in the treatment of complicated urinary-tract 
infections, including pyelonephritis: a randomised, double-blind, phase 3 trial 
(ASPECT-cUTI). Lancet 2015; 385: 1949-56. 
51. Chu H, Zhao L, Wang M, et al. Sulbactam-based therapy for Acinetobacter 
baumannii infection: a systematic review and meta-analysis. Braz J Infect Dis 
2013; 17:389-94. 
52. Matthews P, Alpert M, Rahav G, et al. A randomized trial of tigecycline versus 
ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of 
complicated skin and skin structure infections. BMC Infect Dis 2012, 12:297-
306 
53. Shields RK, Chen L, Cheng S, et al. Emergence of ceftazidime-avibactam 
resistance due to plasmid-borne blaKPC-3 mutations during treatment of 
carbapenem-resistant Klebsiella pneumoniae infections.  Antimicrob Agents 
Chemother. 2017; 61: pii:e02097-16  
54. Rhodes A, Phillips G, Beale R, et al. The Surviving Sepsis Campaign bundles 
and outcome: results from the International Multicentre Prevalence Study on 
Sepsis (the IMPreSS study).Intensive Care Med. 2015; 41:1620-8.  
55. Davey P, Marwick CA, Scott CL,  et al. Interventions to improve antibiotic 
prescribing practices for hospital inpatients. Cochrane.Database.Syst.Rev., 
2017; 2. CD003543. DOI: 10.1002/14651858.CD003543.pub4. 
56. NICE Antimicrobial Stewardship 2015. Medicines Practice Guideline. 
https://www.nice.org.uk/guidance/GID-
ANTIMICROBIALSTEWARDSHIP/documents/antimicrobial-stewardship-
guideline-consultation3 
57. Lew KK, Ng TM, Tan M, et al. Safety and clinical outcomes of carbapenem de-
escalation as part of an antimicrobial stewardship programme in an ESBL-
endemic setting. J Antimicrob Chemother. 2015; 70:1219-25 
58. Kennedy H, Wilson S, Marwick C, Malcolm W, Nathwani D. Reduction in 
broad-spectrum Gram-negative agents by diverse prescribing of aztreonam 
within NHS Tayside. J Antimicrob Chemother. 2015; 70:2421-3.  
59. Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy for 
carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2014; 
69:2305-9.  
60. Ni W, Cai X, Wei C, et al. Efficacy of polymyxins in the treatment of 
carbapenem-resistant Enterobacteriaceae infections: a systematic review and 
meta-analysis. Braz J Infect Dis.2015; 19:170-80.  
61. Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-
producing Klebsiella pneumoniae: differences in therapy and mortality in a 
multicentre study. J Antimicrob Chemother. 2015; 70:2133-43.  
62. Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, et al. Gentamicin 
therapy for sepsis due to carbapenem-resistant and colistin-resistant 
Klebsiella pneumoniae. J Antimicrob Chemother. 2015 ;70:905-13. 
63. Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the 
treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011; 11; 
834-44.  
64. Sandiumenge A, Diaz E, Rodriguez A, et al. Impact of diversity of antibiotic 
use on the development of antimicrobial resistance. J Antimicrob Chemother 
2006; 57, 1197–1204 
65. Pea F, Viale P, Cojutti P, et al. Dosing Nomograms for Attaining Optimum 
Concentrations of Meropenem by Continuous Infusion in Critically Ill Patients 
with Severe Gram-Negative Infections: a Pharmacokinetics/ 
Pharmacodynamics-Based Approach. Antimicrob Agents Chemother. 2012; 
56: 6343–6348.  
66. Poulin E, Brown G. Does Prolonged Infusion Allow Lower Daily Dose of 
Meropenem than Bolus Dosing? Can J Hosp Pharm. 2009; 62: 522.  
67.  Viale P, Tumietto F, Giannella M et al. Impact of a hospital-wide multifaceted 
programme for reducing carbapenem-resistant Enterobacteriaceae infections 
in a large teaching hospital in northern Italy. Clin Microbiol Infect. 
2015;21:242-7. 
68. Niwa T, Shinoda Y, Suzuki A, et al. Outcome measurement of extensive 
implementation of antimicrobial stewardship in patients receiving intravenous 
antibiotics in a Japanese university hospital. Int J Clin Pract. 2012;66:999-
1008.  
69. Lee TC, Frenette C, Jayaraman D, et al. Antibiotic self-stewardship: trainee-
led structured antibiotic time-outs to improve antimicrobial use. Ann Intern 
Med. 2014;161(10 Suppl):S53-8. 
70. Takesue Y, Nakajima K, Ichiki K, et al. Impact of a hospital-wide programme 
of heterogeneous antibiotic use on the development of antibiotic-resistant 
Gram-negative bacteria. J Hosp Infect. 2010;75:28-32.  
71. Panesar P, Jones A, Aldous A, et al. Attitudes and Behaviours to Antimicrobial 
Prescribing following Introduction of a Smartphone App. PLoS One. 
2016;11:e0154202.  
72. Cunney R, Abdel Aziz H, Schubert D, et al. Interpretative reporting and 
selective antimicrobial susceptibility release in non-critical microbiology 
results. J. Antimicrob. Chemother. 2000; 45: 705-708.  
73. Tamma PD, Avdic E, Keenan JF, et al. What is the More Effective Antibiotic 
Stewardship Intervention: Pre-Prescription Authorization or Post-Prescription 
Review with Feedback?  Clin Infect Dis. 2017; 64: 537-543.  
74. Ladenheim D, Cramp E, Patel N.  Are current electronic prescribing systems 
facilitating antimicrobial stewardship in acute National Health Service Hospital 
Trusts in the East of England?  J Hosp Infect 2016; 94: 200-201 
75. Baysari MT, Lehnbom EC, Li L, et al. The effectiveness of information 
technology to improve antimicrobial prescribing in hospitals: A systematic 
review and meta-analysis. Int J Med Inform. 2016: 92: 15-34.  
76. Public Health England 2016. AMR local Indicators. 
http://fingertips.phe.org.uk/profile/amr-local-indicators/data#page/0 
 
 Further reading 
Scottish Antimicrobial Prescribing Group.2016. Position paper on optimising 
antimicrobial prescribing in possible or suspected infections due to multi-drug 
resistant Gram negative bacteria.  
https://www.scottishmedicines.org.uk/files/sapg1/Position_paper_to_Optimise_Antimi
crobial_Prescribing_in_MDRGNB.pdf 
